I Mab Financials

IMAB Stock  USD 0.91  0.01  1.17%   
Based on the measurements of operating efficiency obtained from I Mab's historical financial statements, I Mab is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, I Mab's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 468.7 M, whereas Short and Long Term Debt Total is forecasted to decline to about 16.1 M. Key indicators impacting I Mab's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio4.555.11
Fairly Down
Slightly volatile
The financial analysis of I Mab is a critical element in measuring its lifeblood. Investors should not minimize I Mab's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(1.39 Billion)

  
Understanding current and past I Mab Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of I Mab's financial statements are interrelated, with each one affecting the others. For example, an increase in I Mab's assets may result in an increase in income on the income statement.
Please note, the presentation of I Mab's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, I Mab's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of I Mab's management manipulating its earnings.

I Mab Stock Summary

I Mab competes with Krystal Biotech, Immunovant, Foghorn Therapeutics, Shattuck Labs, and Monte Rosa. I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 378 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS44975P1030
CUSIP44975P103
LocationChina
Business Address2440 Research Boulevard,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteir.i-mabbiopharma.com
Phone240 745 6330
CurrencyUSD - US Dollar

I Mab Key Financial Ratios

I Mab Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets6.3B5.6B4.1B2.6B3.0B3.7B
Other Current Liab567.4M593.3M637.3M402.9M463.4M468.7M
Other Liab2.5M3.9M125.0M335.8M386.2M405.5M
Net Tangible Assets(1.3B)(2.3B)5.3B4.3B5.0B5.2B
Net Debt(4.7B)(3.4B)(3.1B)(2.0B)(1.8B)(1.9B)
Retained Earnings(2.0B)(4.4B)(6.8B)(8.3B)(7.5B)(7.1B)
Accounts Payable67.7M(3.9M)(2.4M)(33.1M)(29.8M)(28.3M)
Cash4.8B3.5B3.2B302.1M347.4M330.0M
Other Assets18.3M2.0M26.6M237.3M272.9M286.6M
Net Receivables130.5M286.9M4.8M2.5M2.9M2.8M
Inventory(422.9M)27.2M(80.3M)12.8M11.5M12.1M
Other Current Assets195.5M190.8M172.5M31.8M28.6M27.2M
Total Liab706.6M1.0B1.1B894.8M805.3M1.4B
Net Invested Capital5.6B4.6B3.0B1.8B2.1B1.9B
Short Long Term Debt80M50M19.0M30.0M27.0M44.5M
Total Current Assets5.3B4.8B3.6B2.3B2.7B3.2B
Net Working Capital4.8B4.2B3.0B1.9B2.2B2.6B
Short Term Debt(33.6M)30.7M22.4M7.3M6.6M6.3M
Intangible Assets120.4M119.7M118.9M16.7M15.0M14.2M

I Mab Key Cash Accounts

202020212022202320242025 (projected)
Investments11.8M(697.3M)458.4M102.5M117.9M123.8M
Change In Cash3.6B(1.2B)(212.9M)(1.1B)(999.4M)(949.4M)
Free Cash Flow425.6M(1.0B)(1.1B)(1.3B)(1.2B)(1.1B)
Depreciation23.1M34.1M63.8M7.4M8.6M8.1M
Other Non Cash Items(313.3M)321.2M431.5M(1.3B)(1.1B)(1.1B)
Capital Expenditures8.0M29.9M45.8M1.6M1.8M1.7M
Net Income470.9M(2.3B)(2.5B)(206.8M)(186.1M)(195.4M)
End Period Cash Flow4.8B3.5B3.3B2.2B2.5B2.7B
Change To Netincome(32.5M)384.1M180.8M932.1M1.1B1.1B

IMAB Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining I Mab's current stock value. Our valuation model uses many indicators to compare I Mab value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across I Mab competition to find correlations between indicators driving I Mab's intrinsic value. More Info.
I Mab is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, I Mab's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the I Mab's earnings, one of the primary drivers of an investment's value.

I Mab Systematic Risk

I Mab's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. I Mab volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was sixty with a total number of output elements of one. The Beta measures systematic risk based on how returns on I Mab correlated with the market. If Beta is less than 0 I Mab generally moves in the opposite direction as compared to the market. If I Mab Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one I Mab is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of I Mab is generally in the same direction as the market. If Beta > 1 I Mab moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in I Mab Stock are looking for potential investment opportunities by analyzing not only static indicators but also various I Mab's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of I Mab growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0156

At present, I Mab's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

I Mab March 4, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of I Mab help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of I Mab. We use our internally-developed statistical techniques to arrive at the intrinsic value of I Mab based on widely used predictive technical indicators. In general, we focus on analyzing IMAB Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build I Mab's daily price indicators and compare them against related drivers.

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Money Managers
Screen money managers from public funds and ETFs managed around the world
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Transaction History
View history of all your transactions and understand their impact on performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges